Price: $70.91
· 1 day: +0.63% · 5 days: +2.04% · 1 month: +5.68% · YTD: +3.97%
As of 2026-11-06 20:56 UTC.
52-week range: $65.65 – $85.03 (currently at 27% of the range).
GSKH is in a turning down, momentum firm. $71.74 is the level overhead; $70 the first support below.
3 of 6 technical checks lean bullish.
| Trend | Turning down · above 50-day & below 200-day |
|---|---|
| Momentum | RSI 54.75 · bearish · MACD bullish |
| Trend strength | ADX 13.8 · weak or range |
| Location | +2.2% vs 50-day MA |
| 52-week range | -16% from high · +8% from low |
| Volatility | ATR 1.23 · ~1.7%/day |
| Level | Type | Distance |
|---|---|---|
| $71.74 (resistance) | swing zone | 1.17% |
| $73.21 (resistance) | swing zone | 3.25% |
| $75.17 (resistance) | swing zone | 6.01% |
| $70.0 (support) | round | -1.28% |
| $69.39 (support) | sma 50 | -2.14% |
| $68.69 (support) | swing zone | -3.13% |
| RSI (14) | 54.75 | MACD | 0.2977 |
|---|---|---|---|
| ADX (14) | 13.8 | ATR (14) | 1.23 |
| 50-day average | $69.39 | 200-day average | $73.3 |
Report of 2026-11-07.
GSKH has climbed roughly 2% over the past five sessions while the S&P 500 fell 2.7%, a divergence that pushed the fund from bearish to neutral on the 2–6 week horizon. The move reflects a countertrend rally against a weekly downtrend that remains intact: the price sits below its 40-week average, and conviction is low because the math from a downside breakout does not clear the 3-to-1 threshold that would make a directional bet worth the risk.
The catalyst was GSK Plc's October 28 quarterly report, which showed a 3% operating profit gain driven by legacy products but a sharp decline in vaccine sales that sent the stock down as much as 5.4% in early London trading — its steepest drop in six months. That is the company-level event. The ETF, however, held relatively steady over the five days surrounding the report, gaining 2.04% while SPY lost 2.70%. The divergence suggests GSKH's basket contains enough offsetting names or has enough non-GSK exposure that the vaccine miss did not cascade through the fund the way a single-stock plunge might suggest.
The offsetting narrative came from GSK's oncology push. On October 26, the company presented promising clinical data at the European Society for Medical Oncology meeting, showing positive results for treatments targeting ovarian and lung cancers. That product news arrived before the earnings report and likely helped stabilize the ETF's price action even as the vaccine story dominated headlines. The two events — one bearish, one bullish — arrived within days of each other and roughly canceled, leaving GSKH in a holding pattern near $71.
The euro's weakness adds a structural tailwind for European exporters like GSK. The currency has fallen more than 5% against the dollar year-to-date and roughly 2% in the past month alone, which benefits firms selling goods and services outside the eurozone. This backdrop supports the argument that European pharma exporters could see earnings lift in the current reporting season. Whether that lift is already priced into GSKH is another question — the fund is up 3.97% year-to-date against SPY's 7.83%, meaning it has underperformed the broad market over the longer stretch.
The long-term thesis is intact but under pressure. GSKH trades below its 40-week average, confirming the weekly downtrend, and sits 16.4% below its 52-week high of $84.82. The 200-day comparison to SPY shows the fund down 4.4% on that basis. This is not a broken trend — the price has not collapsed — but it is a trend that has not yet demonstrated the durability that would warrant high conviction in either direction.
Over the next 2–6 weeks, the balance of evidence leans negative but without strength. A rally against the weekly downtrend that is not yet stretched describes the current situation: the price has risen 5.7% over the past month while SPY fell 5.4%, outpacing the market by 6.4% on a 50-day basis. That relative strength is notable. However, conviction is low — zero of four possible points — because the structure remains below the swing zone at $71.74 where sellers have shown up on prior rallies. The RSI at 53.64 is neither overbought nor oversold, leaving room for the move to continue or reverse without extreme readings.
The strongest case against a bearish lean is that the price has held above the 50-day average at $69.39 and has not broken the recent range low. The prior bearish assessment on October 22 had a weekly close above $69.57 as its invalidation level; the price has since moved higher, which is why the stance shifted. The counterargument is that this is a range-bound move within a larger downtrend, and a close below $70.00 would confirm the downside breakout that the structure is pointing toward. That does not tip the balance toward higher conviction, but it explains why the stance is neutral rather than cautiously bullish.
The structure holds below $71.74, the swing zone where sellers have appeared on rallies. The weekly trend would end above $73.21 — another swing zone — and that level is where the picture would shift from neutral toward a more constructive reading. Below current price, $70.00 is a round number that has acted as support in recent sessions. The 50-day average at $69.39 sits just below that, and the next swing zone at $68.69 is the next support after that.
A downside breakout would be confirmed by a daily close below $70.00. From there the math gives a target at $69.39 (the 50-day average), which offers a reward-to-risk ratio of 0.3 against the stop at $72.04. The next target at $68.69 improves the ratio to 0.6. Neither target clears the 3-to-1 threshold that would make the breakout worth the risk. To reach that threshold, the downside target would need to extend further — a move that would require the price to break through both the 50-day average and the $68.69 swing zone before finding a meaningful support level.
A weekly close above $73.21 would shift the picture, as that is the swing zone where the trend would end and the structure would flip from resistance to support. Beyond price, a durable shift in the pharma-vaccine narrative — such as a major partnership announcement or a regulatory win that reframes the vaccine business as a growth story rather than a declining one — would be the non-price fact that could change the reading. As of now, the evidence does not support that shift.
Interactive GSKH chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs